FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum

SHILPAMED Share Price Discussion

Shilpa Medicare Ltd.
NSE: SHILPAMED | BSE: 530549 | ISIN: INE790G01031 | Sector: Pharmaceuticals and health care

SHILPAMED Rating

5/5 (1 Ratings)
SHILPAMED Share Price *
461 +21.95 (5%)
* (quote may be delayed)
Find answers to all your questions on live SHILPAMED message board: Is SHILPAMED buy or sell? Should I buy SHILPAMED shares? Why are SHILPAMED shares falling? Should I invest in SHILPAMED stock?

You can also check SHILPAMED share price target recommended by brokerages.

SHILPAMED Discussion Forum

@stocktrendr • Reputation: 319

Shilpa Medicare: US FDA audit has been completed at its API sites at Raichur District, Karnataka between 3rd and 7th Feb, 2020 with "ZERO" observations
Like
reply
Reply
@ygtrader • Reputation: 1,690
ElliottWave Master in SHILPAMED
Target met! Strong returns

Posted to buy at
304.5
Made highs of 410
Over 100+ points.
Like
reply
Reply
@ygtrader • Reputation: 1,690
ElliottWave Master in SHILPAMED
SHILPAMED
Trade entered: Buy SHILPAMED @304.5 Target@320 ...

Target met!
Strong returns
Like
reply
Reply
@newsbot • Reputation: 2,308
Shilpa Medicare share price gains nearly 6% on USFDA nod
The company has received USFDA tentative approval for its ANDA Pirfenidone tablets.
Moneycontrol
Like
reply
Reply
@stocktrendr • Reputation: 319

Shilpa Medicare: Company gets tentative US FDA nod for generic of Esbriet drug
Like
reply
Reply
@newsbot • Reputation: 2,308
Stocks in the news: M&M, Maruti, Coal India, Tata Motors, Alkem Labs, Indian Bank
Relaxo Footwears | Thyrocare Technologies | Infoedge | Indian Bank | Mahindra & Mahindra | Maruti | Alkem Labs are some of the stocks which are in news today.
Moneycontrol
Like
reply
Reply
@ygtrader • Reputation: 1,690
SHILPAMED

Type
Buy
Instrument
SHILPAMED
Entry Price
₹304.5
Price@Trade
₹304.5
Target Price
₹320
Stop Price
₹290
Valid Till
Feb 7, 2020 3:20 PM
Margin
₹304.5 approx for 1 Qty
Status
Target Achieved
Exit Price
₹320
Net P&L
5.09% Profit
Like
reply
Reply (1)
Latest replies
TrackerBot @trackerbot
Feb 4 3:13 PM

Update
Target Achieved
Exit Price
₹320
@newsbot • Reputation: 2,308
Stocks in the news: HUL, ITC, Divis Lab, Castrol, Power Grid, JSPL, IndoStar Capital
HUL | ITC | Vedanta | Castrol | Power Grid | Amara Raja Batteries and J&K Bank are among the stocks that are in the news today.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Shilpa Medicare zooms 5% after USFDA concludes inspection of Telangana facility
The stock witnessed spurt in volume by more than 1.17 times. It was trading with volumes of 3,249 shares, compared to its five-day average of 1,886 shares, an increase of 72.27 percent.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Stocks in the news: Canara Bank, NBCC, PNB, DHFL, Shilpa Medicare, Avenue Supermarts
Vivimed Labs | Canara Bank | DHFL | Varun Beverages and Rane Holdings are stocks, which are in news today.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Top 10 stocks that rose or fell in the week
The S&P BSE Midcap index shed 1.31 percent, Smallcap Index was down 0.90 percent and S&P BSE Largecap Index fell 0.59 percent last week.
www.moneycontrol.com
Like
reply
Reply
@newsbot • Reputation: 2,308
Shilpa Medicare gets 5 observations from USFDA for its Raichur facility
"We have completed USFDA (United States Food and Drug Administration) audit at our API (active pharmaceutical ingredient) site, Raichur between July 22-26, 2019," Shilpa Medicare said in a filing to the BSE.
www.moneycontrol.com
Like
reply
Reply
@newsbot • Reputation: 2,308
Like
reply
Reply
@newsbot • Reputation: 2,308
Like
reply
Reply
@newsbot • Reputation: 2,308
Like
reply
Reply
@newsbot • Reputation: 2,308
Like
reply
Reply
@newsbot • Reputation: 2,308
Like
reply
Reply
@newsbot • Reputation: 2,308
Like
reply
Reply
@newsbot • Reputation: 2,308
Like
reply
Reply
@newsbot • Reputation: 2,308
Like
reply
Reply
@newsbot • Reputation: 2,308
Like
reply
Reply
  • SHILPAMED - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization2,772.63
    Enterprise Value2,841.7
    Price to Earnings28.49
    Price to Book Value2.16
    Return on Capital Employed0.13
    Return on Equity0.12
    Face Value1
    Dividend YieldNA
  • SHILPAMED Share Price - Technicals

    keyboard_arrow_down
    SHILPAMED - 52 Week High₹491
    SHILPAMED - 52 Week Low₹208.1
  • SHILPAMED - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    8-Feb-19Motilal OswalBuy480
    21-Jan-19Motilal OswalBuy620
    15-Nov-18Motilal OswalBuy575
    14-Aug-18Motilal OswalBuy620
    3-Apr-18Motilal OswalBuy686
    SHILPAMED Brokerage Price Target
  • SHILPAMED Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Feb 19443461443461
    Feb 18423448408.85439.05
    Feb 17452459.9430.35430.35
    Feb 14472489448.95452.95
    Feb 13487491456472.55
  • SHILPAMED Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹363.14
    30 Day Moving Average₹331.74
    50 Day Moving Average₹313.57
    100 Day Moving Average₹301.46
    200 Day Moving Average₹313.09
  • SHILPAMED - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue741733.420.01
    Operating Profit179182.23-0.02
    Profit Before Tax167170.29-0.02
    Net Income133126.590.05
  • SHILPAMED - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds1,2811,1570.11
    Total Liabilities387425-0.09
    Total Assets1,6681,5820.05
  • SHILPAMED - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity5438.290.41
    Cash from Investing Activity-13-266.89-0.95
    Cash from Financing Activity-62316.32-1.2
    Net Cash Flow-2087.72-1.23
  • SHILPAMED - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.080.09
    Return on Equity0.120.13
    Return on Capital Employed0.130.15
  • SHILPAMED - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.31
    3 Year CAGR Growth in Operating Profit0.31
    3 Year CAGR Growth in EBIDTA0.42
    3 Year CAGR Growth in Net Income0.58
    3 Yr CAGR Growth - Diluted EPS-0.25
  • SHILPAMED - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue1.26
    5 Year CAGR Growth in Operating Profit1.74
    5 Year CAGR Growth in EBIDTA1.87
    5 Year CAGR Growth in Net Income1.89
    3 Yr CAGR Growth - Diluted EPS-0.13
  • SHILPAMED - Recent News

    keyboard_arrow_down
    NewsBot
    Feb 3 4:03 PM
    Shilpa Medicare share price gains nearly 6% on USFDA nod
    Moneycontrol
    NewsBot
    Feb 3 1:43 PM
    Stocks in the news: M&M, Maruti, Coal India, Tata Motors, Alkem Labs, Indian Bank
    Moneycontrol
    NewsBot
    Feb 1 1:18 PM
    Stocks in the news: HUL, ITC, Divis Lab, Castrol, Power Grid, JSPL, IndoStar Capital
    Moneycontrol
    NewsBot
    Sep 9 5:28 PM
    Shilpa Medicare zooms 5% after USFDA concludes inspection of Telangana facility
    Moneycontrol
    NewsBot
    Sep 9 1:43 PM
    Stocks in the news: Canara Bank, NBCC, PNB, DHFL, Shilpa Medicare, Avenue Supermarts
    Moneycontrol
    NewsBot
    Aug 17 6:58 PM
    Top 10 stocks that rose or fell in the week
    www.moneycontrol.com
    NewsBot
    Jul 30 1:18 AM
    Shilpa Medicare gets 5 observations from USFDA for its Raichur facility
    www.moneycontrol.com
    NewsBot
    Apr 22 2:08 PM
    NewsBot
    Feb 25 4:57 PM
    NewsBot
    Feb 25 4:17 PM
  • SHILPAMED - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. S...
    Aurobindo Pharma Ltd. Sector: Pharma...
    Biocon Ltd. Sector: Pharmaceuticals ...
    Cipla Ltd. Sector: Pharmaceuticals a...
    Dr. Reddy's Laboratories Ltd. Sector...
    Lupin Ltd. Sector: Pharmaceuticals an...
    Piramal Enterprises Ltd. Sector: Phar...
    Divi's Laboratories Ltd. Sector: Pha...
    Glenmark Pharmaceuticals Ltd. Sector...
    Strides Pharma Science Ltd. Sector: P...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.